Biocon Limited

Biocon Limited

Biocon Limited has informed the Exchange about the remittance of final dividend for the FY 2025-26, with a dividend of ₹ 0.50 per equity share.

Biocon Limited

Biocon Limited has received marketing approval for its pegfilgrastim biosimilar from Japan's Ministry of Health, Labour and Welfare (MHLW). This approval strengthens Biocon's portfolio of biosimilar products in Japan and reaffirms the company's commitment to increasing patient access to high-quality and affordable medications globally.

Biocon Limited

Biocon Limited's US subsidiary has received US FDA approval for Yesintek (ustekinumab-kfce) single-dose prefilled autoinjector, expanding its immunology product portfolio in the US.

Biocon Limited

Biocon Limited has informed the Exchange about a scheduled meeting with analysts/institutional investors at the 22nd Annual Global Investor Conference in Mumbai on August 17, 2026.

Biocon Limited

Biocon Limited has informed the Exchange about the transcript of its Q1 FY27 Earnings Conference Call, which was held on August 06, 2026. The transcript is available on the company's website.

Biocon Limited

Biocon Limited has submitted the Exchange a copy of the Srutinizers report of the 48th Annual General Meeting held on August 06, 2026, and informed the Exchange regarding voting results.

Biocon Limited

Biocon Limited has informed the Exchange about the schedule of meetings with analysts/institutional investors, as per SEBI Listing Regulations.

Biocon Limited

Biocon Limited has informed the Exchange about the schedule of meetings with analysts/institutional investors, as per SEBI Listing Regulations.

Biocon Limited

Biocon Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 43,360 million and profit attributable to shareholders at Rs. 1,411 million.

Biocon Limited

Biocon Limited has informed the Exchange regarding the resignation of B S R & Co. LLP as the statutory auditors of its material subsidiary, Biocon Biologics Limited, effective August 06, 2026, due to mandatory rotation of the auditors of the holding company.

Biocon Limited

Biocon Limited has informed the Exchange regarding changes in its Directors and Statutory Auditors at the 48th Annual General Meeting (AGM) held on August 06, 2026. The changes include the re-appointment of Mr. Eric Vivek Mazumdar as Director liable to retire by rotation, the appointment of S.R. Batliboi & Associates LLP as Statutory Auditors, and the retirement of Mr. Nicholas Robert Haggar as an Independent Director.

Biocon Limited

Biocon Limited has informed the Exchange regarding Change in Auditors of the company. The company has re-appointed Mr. Eric Vivek Mazumdar as Director liable to retire by rotation, appointed S.R. Batliboi & Associates LLP as the Statutory Auditors, and retired Mr. Nicholas Robert Haggar as an Independent Director.

Biocon Limited

Biocon Limited has informed the Exchange regarding the re-appointment of Mr. Eric Vivek Mazumdar as Non-Executive Director of the company, effective August 06, 2026, and the appointment of S.R. Batliboi & Associates LLP as the Statutory Auditors of the company for a term of 5 years.

Biocon Limited

Biocon Limited held its 48th Annual General Meeting on August 06, 2026, through video conferencing, with 90 members present. The meeting was attended by the Executive Chairperson, Managing Director, and several directors, as well as key managerial personnel and statutory auditors.

Biocon Limited

Biocon Limited has informed the Exchange about the link to the recording of its Q1 FY27 Earnings Call, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Biocon Limited

Biocon Limited has announced its Q1 FY27 earnings, with revenue from operations at ₹4,336 crore, a 10% YoY growth. The company's biosimilars segment saw a 16% YoY growth, driven by the North America market, while the generics segment reported a 21% YoY growth. The company has also announced the EMA approval for its second insulin drug product line in Malaysia, which is expected to support future growth.

Biocon Limited

Biocon Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, as required by SEBI regulations, indicating no deviation from the objects of the Qualified Institutions Placement (QIP) and confirming the utilization of proceeds.

Biocon Limited

Biocon Limited announced its consolidated financial results for the fiscal first quarter ended June 30, 2026, with a total income of Rs 4,391 Cr, up 9% YoY, driven by strong growth in the Biopharma business. The company reported a net profit of Rs 141 Cr, up 355% YoY.

Biocon Limited

Biocon Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 638 million and revenue from operations of Rs. 6,245 million.

Biocon Limited

Biocon Limited has announced the commercial launch of Yesafili, a biosimilar to Regeneron's Eylea 2 mg, in the United States. The product was approved by the U.S. FDA in May 2024 and has been granted interchangeable designation, allowing substitution at the pharmacy level in accordance with state laws.